CVRx price target raised to $15 from $12 at Lake Street

Lake Street raised the firm’s price target on CVRx (CVRX) to $15 from $12 and keeps a Buy rating on the shares. In the “interest of conservatism,” the firm is decreasing its revenue estimate for 2025 to 25% year-over-year growth, but it thinks this “leaves room for upside with solid execution” and contends that CVRx “continues to have the full recipe for a successful MedTech growth story with durable mid to high 20% growth.”